Few women eligible for taking medication for breast cancer prevention

September 27, 2004

CHICAGO - A survey conducted in primary care practices showed that a small proportion of women are eligible for discussions about use of tamoxifen to prevent cancer, and of those women, the proportion of breast cancers that would be prevented is also small, according to an article in the September 27 issue of The Archives of Internal Medicine, one of the JAMA/Archives journals.

Despite the importance of screening mammography and breast examination in breast cancer control, randomized trials show modest effect of screening on breast cancer deaths, according to background information in the article. A national breast cancer prevention trial showed a 49 percent reduction in breast cancer incidence in high-risk individuals who received tamoxifen. However, according to the article, the same study also showed that the drug increased the risk of endometrial (uterus) cancer, pulmonary embolism (sudden blockage of an artery in the lung), blood clots in the deep veins, and stroke.

Carmen L. Lewis, M.D., M.P.H., from The University of North Carolina at Chapel Hill, and colleagues surveyed 605 women aged 40 to 69 years in ten general internal medicine practices in North Carolina in 2000. The survey was designed to determine each woman's breast cancer risk and then to assess eligibility for chemoprevention (using tamoxifen to prevent breast cancer). The researchers determined the women's five-year breast cancer risk based on age, ethnicity, number of first-degree relatives with breast cancer, age at first menstruation, age at first live birth, number of breast biopsies, and presence of atypical hyperplasia (abnormal cells that may be indicative of cancer) in a biopsy specimen. Women with an estimated five-year breast cancer risk of at least 1.66 percent were defined as having an increased breast cancer risk. To determine the possible risks of taking tamoxifen, the women were questioned about their medical history; specifically, whether their physicians had told them they had high blood pressure, diabetes mellitus, blood clots in the legs, or blood clots in the lungs.

The researchers found that among white women, nine percent in their 40s, 24 percent in their 50s, and 53.4 percent in their 60s had a five-year estimated breast cancer risk of 1.66 percent or greater. Among black women, 2.9 percent in their 40s, 7.1 percent in their 50s, and 13 percent in their 60s had a similar risk. When the possible side effects of tamoxifen were considered in white women, ten percent or fewer in all age groups were judged to be potentially appropriate for chemoprevention using tamoxifen. In women identified as at an increased risk for breast cancer, the maximum proportion of breast cancers that would be prevented was 6 to 8.3 percent, according to the researchers' calculations.

The authors write: "Small numbers of women in primary care practices are eligible for discussions about chemoprevention; the maximum proportion of breast cancers prevented is also small. Challenges lie in targeting discussions to the most appropriate women and in finding new chemoprevention strategies that have less risk of harms."

(Arch Intern Med. 2004; 164: 1897 - 1903. Available post-embargo at www.archinternmed.com)

Editor's note: This study was supported by a grant from the National Cancer Institute, Bethesda, Md., and The University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, and by a grant from the Agency for Healthcare Research and Quality, Rockville, Md. Dr. Lewis is the recipient of a Cancer Control Career Development Award for Primary Care Physicians from the American Cancer Society, Atlanta, Ga.
To contact Carmen L. Lewis, M.D., M.P.H., call David Williamson at 919-962-8596.

For more information, contact JAMA/Archives Media Relations at 312-464-JAMA (5262) or e-mail mediarelations@jama-archives.org.

The JAMA Network Journals

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.